Ben Stone joined AnaptysBio in May 2022 to lead the company’s Corporate Development functions. Prior to joining AnaptysBio, Mr. Stone was an Operating Principal at Two River, where he co-founded and held interim senior leadership roles in 76Bio and IconoVir Bio. Previously, Ben led the Corporate Strategy function at Spark Therapeutics until its acquisition by Roche, and was a member of the Healthcare Investment Banking Group at Credit Suisse. Mr. Stone has earned a B.S. in Finance from the Wharton School of the University of Pennsylvania and a B.A. in International Studies from the University of Pennsylvania.